NEW YORK — AI diagnostics firm Tempus said Monday that it has formed a cancer drug research and development partnership with South Korea's JW Pharmaceutical.
Under the terms of the deal, the companies will use Tempus' biological modeling platform and collection of patient-derived cancer organoid models to screen JW Pharma's early pipeline assets, identify biomarkers of response, and guide asset prioritization decisions.
Each model, Tempus said, reflects the biology of a distinct patient tumor and is linked to multimodal data generated using the company's xT next-generation sequencing assay.
Financial and other terms were not disclosed.
Through the collaboration, Tempus and JW Pharma are "curating a panel of organoids across specific cancer indications that closely reflect real-world patients to evaluate select preclinical candidates, and we are excited to understand the full potential of this innovative approach to early research," Tempus Chief Operating Officer Ryan Fukushima said in a statement.
Chicago-based Tempus, which went public earlier this year, partnered with Avacta Therapeutics last week to advance that firm's precision oncology platform. It also recently expanded a cancer R&D alliance with Takeda and formed a multiyear collaboration with BioNTech.